Bausch Health Companies (NYSE:BHC) Price Target Raised to $9.50

Bausch Health Companies (NYSE:BHC – Get Rating) had its price target raised by Jefferies Financial Group from $7.00 to $9.50 in a research report released on Monday, The Fly reports.

Separately, StockNews.com started coverage on shares of Bausch Health Companies in a research report on Thursday, May 18th. They set a hold rating on the stock. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company currently has a consensus rating of Hold and a consensus price target of $8.88.

Bausch Health Companies Trading Down 1.0 %

NYSE:BHC opened at $8.20 on Monday. Bausch Health Companies has a 12 month low of $4.00 and a 12 month high of $10.23. The company has a 50 day simple moving average of $7.32 and a two-hundred day simple moving average of $7.55. The company has a current ratio of 1.08, a quick ratio of 0.77 and a debt-to-equity ratio of 139.36. The company has a market cap of $2.97 billion, a PE ratio of -8.37, a price-to-earnings-growth ratio of 0.12 and a beta of 0.98.

Bausch Health Companies (NYSE:BHC – Get Rating) last issued its earnings results on Thursday, February 23rd. The company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.10. Bausch Health Companies had a negative net margin of 4.38% and a positive return on equity of 381.67%. The business had revenue of $2.19 billion for the quarter, compared to the consensus estimate of $2.12 billion. Research analysts forecast that Bausch Health Companies will post 3.37 earnings per share for the current year.

Hedge Funds Weigh In On Bausch Health Companies

A number of large investors have recently made changes to their positions in BHC. JPMorgan Chase & Co. boosted its position in Bausch Health Companies by 11.8% during the first quarter. JPMorgan Chase & Co. now owns 51,271 shares of the company’s stock worth $415,000 after purchasing an additional 5,424 shares during the period. Thrivent Financial for Lutherans acquired a new stake in shares of Bausch Health Companies in the first quarter valued at $1,490,000. First Trust Advisors LP increased its position in Bausch Health Companies by 56.9% in the first quarter. First Trust Advisors LP now owns 95,609 shares of the company’s stock worth $774,000 after purchasing an additional 34,658 shares during the period. Brookfield Corp ON bought a new position in Bausch Health Companies during the first quarter worth about $932,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in Bausch Health Companies by 14.5% during the first quarter. Cubist Systematic Strategies LLC now owns 688,311 shares of the company’s stock worth $5,575,000 after buying an additional 87,255 shares during the last quarter. Institutional investors and hedge funds own 66.99% of the company’s stock.

Bausch Health Companies Company Profile

(Get Rating)

Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb.